NEW YORK (GenomeWeb) – Meridian Bioscience today initiated revenue and earnings guidance for its fiscal 2016 and said that revenues and earnings for fiscal 2015 are expected to be at the low end of its previously stated guidance range. 

The firm said that for fiscal 2016, which starts on Oct. 1, it expects net revenues to grow between 3 percent and 5 percent on a constant currency basis, translating to a revenue range of $195 million to $200 million. EPS is expected to be in the range of $.86 to $.90. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.

Sponsored by

This webinar will discuss how understanding the relative performance characteristics of glass and polymer substrates for in vitro diagnostic applications such as microarrays and microfluidics can help to optimize diagnostic performance.

Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the National Institutes of Health evaluated a novel in situ hybridization approach and applied it to study splice variants related to schizophrenia.

Sponsored by

This webinar will discuss the use of shotgun metagenomics to identify children at risk of hospital-acquired infection.